

United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.	
10/675,339 09/30/2003		Mickey L. Peshoff	P03-0242	5794	
27257	7590 02/02/2006		EXAMINER		
KEATY PR	OFESSIONAL I	PAK, Jo	PAK, JOHN D		
THOMAS S. 2533 AMER		ART UNIT	PAPER NUMBER		
	EN, LA 70767	1616			
			DATE MAILED: 02/02/2006		

Please find below and/or attached an Office communication concerning this application or proceeding.

4		Application	n No.	Applicant(s)					
Office Action Summary		10/675,33	9	PESHOFF, MICK	PESHOFF, MICKEY L.				
		Examiner		Art Unit					
		JOHN PAR	(1616					
Period fo	The MAILING DATE of this communicati or Reply	ion appears on the	cover sheet with the c	correspondence ad	idress				
WHIC - Exter after - If NO - Failu Any (ORTENED STATUTORY PERIOD FOR CHEVER IS LONGER, FROM THE MAIL Insions of time may be available under the provisions of 37 SIX (6) MONTHS from the mailing date of this communicate period for reply is specified above, the maximum statutory re to reply within the set or extended period for reply will, be eply received by the Office later than three months after the patent term adjustment. See 37 CFR 1.704(b).	ING DATE OF TH CFR 1.136(a). In no eve ation. y period will apply and will by statute, cause the appl	IS COMMUNICATION int, however, may a reply be tin I expire SIX (6) MONTHS from ication to become ABANDONE	N. mely filed n the mailing date of this c ED (35 U.S.C. § 133).					
Status									
1)⊠	Responsive to communication(s) filed or	n 14 November 20	005.						
2a)□	This action is FINAL . 2b)⊠ This action is non-final.								
3)									
•	closed in accordance with the practice under Ex parte Quayle, 1935 C.D. 11, 453 O.G. 213.								
Dispositi	on of Claims)						
4) 🖂	Claim(s) <u>1,2,7-9,15-18,22 and 23</u> is/are	pending in the ap	plication.						
•	4a) Of the above claim(s) 18,22 and 23 is/are withdrawn from consideration.								
5)□	5) Claim(s) is/are allowed.								
6)⊠	6)⊠ Claim(s) <u>1,2,7-9 and 15-17</u> is/are rejected.								
7)	7) Claim(s) is/are objected to.								
8)□	8) Claim(s) are subject to restriction and/or election requirement.								
Applicati	on Papers								
9)[The specification is objected to by the Ex	kaminer.							
10)	The drawing(s) filed on is/are: a)[accepted or b)	objected to by the	Examiner.					
	Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).								
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).									
11)[The oath or declaration is objected to by	the Examiner. No	te the attached Office	Action or form P	TO-152.				
Priority (ınder 35 U.S.C. § 119								
12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f). a) All b) Some * c) None of:									
	 Certified copies of the priority documents have been received. 								
	2. Certified copies of the priority documents have been received in Application No								
	3. Copies of the certified copies of the priority documents have been received in this National Stage								
application from the International Bureau (PCT Rule 17.2(a)).									
* See the attached detailed Office action for a list of the certified copies not received.									
Attach==	M a)								
Attachmen 1) Notice	t(s) e of References Cited (PTO-892)		4) Interview Summary	v (PTO-413)					
2) Notic	e of Draftsperson's Patent Drawing Review (PTO-9		Paper No(s)/Mail D	ate					
	nation Disclosure Statement(s) (PTO-1449 or PTO r No(s)/Mail Date <u>9/30/2003</u> .)/SB/08)	5) Notice of Informal F 6) Other:	Patent Application (PT	O-152)				

Art Unit: 1616

Claims 1-2, 7-9, 15-18, and 22-23 are pending in this application.

Applicant's election with traverse of the invention of Group I in the reply filed on 11/14/2005 is acknowledged. Because applicant did not distinctly and specifically point out the supposed errors in the restriction requirement, the election has been treated as an election without traverse (MPEP § 818.03(a)).

Accordingly, claims 1-2, 7-9 and 15-17 will presently be examined to the extent that they read on the mixture of vitamins A, D and E, as explicitly set forth in the Office action of 10/18/2005. Claims 18 and 22-23 are withdrawn from further consideration as being directed to non-elected subject matter.

The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:

A person shall be entitled to a patent unless -

(b) the invention was patented or described in a printed publication in this or a foreign country or in public use or on sale in this country, more than one year prior to the date of application for patent in the United States.

Claims 1-2, 7 and 17 are rejected under 35 U.S.C. 102(b) as being anticipated by Neigut (5,378,461).

Neight explicitly discloses a topical composition for treating skin damage, which contains vitamins A, D and E (see claim 1; see also the table on column 5). There are numerous examples, including one with just olive oil and vitamins A, D and E (column 10, lines 55-58).

Art Unit: 1616

Neigut's disclosure explicitly meets all of the claimed requirements in applicant's claims 1-2, 7 and 17. Since vitamin A is retinol (alternative name) and vitamin E is tocopherol (alternative name), subject matter claims 7 and 17 are explicitly disclosed. The claims are thereby anticipated.

Claims 1-2, 7-9 and 15 are rejected under 35 U.S.C. 102(b) as being anticipated by Thomas (US 4,857,321).

Thomas explicitly discloses an ointment composition that contains retinol palmitate (ingredient p in claims 1-2), cholecalciferol (ingredient x in claim 1 & ingredient w in claim 2), tocopherol acetate (ingredient v in claims 1-2), and a mixture of vitamins A and D_3 (ingredient w in claims 1-2).

It is noted that vitamin A is retinol, retinol palmitate is retinyl palmitate, and vitamin D₃ is cholecalciferol. The claims are thereby anticipated.

Claims 1-2, 8-9 and 15-16 are rejected under 35 U.S.C. 102(b) as being anticipated by Derwent abstract 2000-617480 (abstracting RU 2146921).

Derwent abstract 2000-617480 explicitly discloses a composition for dermatological diseases, which contains retinol palmitate, tocopherol acetate, and ergocalciferol.

Art Unit: 1616

As noted above, retinol palmitate is the same substance as retinyl palmitate. The claims are thereby anticipated.

All claims are anticipated by the explicit disclosures of the prior art. No claim is allowed.

Any inquiry concerning this communication or earlier communications from the Examiner should be directed to JOHN PAK whose telephone number is (571)272-0620. The Examiner can normally be reached on Monday to Friday from 8 AM to 4:30 PM.

If attempts to reach the Examiner by telephone are unsuccessful, the Examiner's SPE, Gary Kunz, can be reached on (571)272-0887.

The fax phone number for the organization where this application or proceeding is assigned is (571)273-8300.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the receptionist whose telephone number is (571)272-1600.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only.

Art Unit: 1616

Page 5

For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

JOHN PAK PRIMARY EXAMINER GROUP 1200